PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Ogilvy Public Relations

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

GVK BIO Inaugurates its New Research Center - A dedicated Chemistry Research Center for Wyeth Pharma at Hyderabad, India [NYSE: WYE]
GVK BIO Inaugurates its New Research Center

 

NewswireToday - /newswire/ - Hyderabad, Andhra Pradesh, India, 2007/10/06 - A dedicated Chemistry Research Center for Wyeth Pharma at Hyderabad, India [NYSE: WYE].

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

GVK Biosciences Private Limited (GVK BIO) today inaugurated the GVK BIO Wyeth Hyderabad Chemistry Center, a built-to-suit research center for Wyeth Pharmaceuticals located in Hyderabad. The Research center was inaugurated by Dr. Robert Ruffolo, Ph.D., President, Wyeth Research, in the presence of Mr. David Hopper, the Consul General, United States Consulate, Chennai, Mr. G V Krishna Reddy, Chairman, GVK Group, Mr. D.S.Brar, Chairman, GVK BIO and Mr. G V Sanjay Reddy, Managing Director, GVK BIO.

A team of 200 synthetic chemists and scientists are working on cutting-edge research in this state-of-the-art facility. The facility is equipped with the latest high-end scientific equipment and instrumentation. The GVK BIO Wyeth Hyderabad Chemistry Center, located at Nacharam is comparable to any international research center.

GVK BIO and Wyeth entered into a collaborative research agreement in 2006. Wyeth selected GVK BIO after a global worldwide search for a suitable chemistry partner. GVK BIO was selected for the strength of their management team, research philosophy, and expertise in the area of Synthetic Organic Chemistry. The current activities include the synthesis of reference standards, building blocks, intermediates, analogues, focused libraries and screening libraries. GVK BIO has a proven capability and track record in delivering value-added scientific services on time.

Mr. G V Krishna Reddy, Chairman, GVK Group said “GVK BIO is our group’s first venture outside of Infrastructure. We are happy with the way GVK BIO has grown rapidly to become India’s leading Contract Research Organization”.

Dr. Ruffolo said “Wyeth has a large discovery portfolio resulting in a growing need for strong medicinal chemistry. By working with GVK BIO as a partner, we are able to tap into the huge chemistry talent pool in India and to work globally on a 24-hour basis. This partnership significantly increases our chemistry capacity and complements our already strong in-house synthetic chemistry efforts.”

“Through this Research partnership, Wyeth has given a strong vote of confidence not only to GVK BIO but on a larger platform to India. Based on the success of the current Medicinal Chemistry projects, we look forward to growing our collaboration in other areas” said Mr. D.S.Brar, Chairman, GVK BIO.

Mr. G.V.Sanjay Reddy said, “GVK BIO has made available the best scientific talent for Wyeth. The facility, human resources and equipment reflect high quality of science and productivity levels. The collaboration has been a win-win for both Wyeth and GVK BIO.”

GVK BIO will be responsible for designing synthetic routes for new molecules, carrying out the synthesis and characterization of target molecules for Wyeth.

About Wyeth

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women’s health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

About GVK BIO
GVK Biosciences, India’s premier Contract Research Organization, delivers integrated research services to big Pharma and Biotech companies globally. The company accelerates the Drug Discovery and Development process of its customers through science and innovation. Currently the company has more than 1,300 employees spread across facilities in Hyderabad, Chennai and Gurgaon.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Ogilvy Public Relations

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


GVK BIO Inaugurates its New Research Center

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sreekar Reddy - Ogilvy.com 
+91 98 66110032 sreekar.reddy[.]ogilvy.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Ogilvy Public Relations securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Ogilvy Public Relations / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Explorers Vacation Club

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)